NTRK1 and neoplasm: TRK signaling leads to the activation of the RAS/MAPK and PI3K/AKT pathways, and TRKC, as well as the other TRKs, has generally been considered to be an oncogenic receptor; however, studies have found that, in certain contexts, TRKC may function as a tumor suppressor [169,170].